About Orexo

Company Description

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of mental illness and substance use disorders. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for the treatment of opioid use disorder.

- Developed four commercial pharmaceutical products with worldwide approval
- Addresses unmet need within the growing space of mental illness and addiction disorders
- Broad product portfolio and development pipeline of traditional pharma products and digital therapies
- Strategic focus on portfolio expansion through development, licensing and M&A
- Strong cash generation from the business area US Pharma enabling to invest in future growth

Year founded


Served area


Shareholder information

Shares outstanding



Nov. 18, 2005

Stock exchange(s)

Nasdaq Stockholm



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.